|
Aug 5
|
Medexus Schedules First Fiscal Quarter 2026 Conference Call
|
|
Aug 5
|
GRAFAPEX (treosulfan) for Injection Receives CMS Approval of New Technology Add-On Payment (NTAP) for Eligible Cases in CMS's Fiscal Year 2026
|
|
Jun 25
|
Medexus Announces Strong Fiscal Year 2025 Results, Including Initial Results from Launch of GRAFAPEX (treosulfan) for Injection in the United States
|
|
Jun 17
|
Medexus Schedules Fourth Fiscal Quarter and Fiscal Year 2025 Conference Call
|
|
Feb 24
|
Medexus Announces Commercial Availability of GRAFAPEX (treosulfan) for Injection
|